Literature DB >> 6432853

Pseudomonas exotoxin-anti-TAC. Cell-specific immunotoxin active against cells expressing the human T cell growth factor receptor.

D J FitzGerald, T A Waldmann, M C Willingham, I Pastan.   

Abstract

An immunotoxin was constructed with an activity that discriminated between two T cell lines based on the expression of the T cell growth factor (TCGF) receptor on their cell surface. A toxic protein conjugate, designated PE-anti-TAC, was made by chemically coupling pseudomonas exotoxin (PE) to a monoclonal antibody (anti-TAC) that recognizes the human TCGF receptor. This conjugate was toxic to HUT-102 cells, a cell line that expresses the TCGF receptor, but was nontoxic for MOLT-4 cells, a receptor-negative line. The toxicity of PE-anti-TAC was enhanced 50-fold in the presence of human adenovirus type II and was reduced to control levels by adding excess anti-TAC antibody. The toxicity of PE-anti-TAC for HUT-102 cells was compared with PE-anti-transferrin receptor. To compare the route of entry for both anti-TAC and anti-TFR using electron microscopy, protein conjugates were made by coupling horseradish peroxidase (HRP) to each antibody. Anti-TFR-HRP entered HUT-102 cells by concentrative adsorptive endocytosis via coated pits, and the majority of the antibodies bound to the cell surface at 4 degrees C were seen in receptosomes by 10 min after warming to 37 degrees C. Anti-TAC-HRP was also found to enter HUT-102 cells via coated pits and receptosomes; but, in contrast to anti-TFR, anti-TAC did not selectively concentrate in coated pits, and therefore the majority of this surface-bound antibody were not internalized in HUT-102 cells by 10 min at 37 degrees C.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6432853      PMCID: PMC425254          DOI: 10.1172/JCI111516

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   19.456


  21 in total

1.  Biochemical studies on adenovirus multiplication. IV. Isolation, purification, and chemical analysis of adenovirus.

Authors:  M GREEN; M PINA
Journal:  Virology       Date:  1963-05       Impact factor: 3.616

2.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

3.  Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells.

Authors:  I S Trowbridge; D L Domingo
Journal:  Nature       Date:  1981-11-12       Impact factor: 49.962

4.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

Authors:  T Uchiyama; S Broder; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

5.  Characterization of a monoclonal antibody (5E9) that defines a human cell surface antigen of cell activation.

Authors:  B F Haynes; M Hemler; T Cotner; D L Mann; G S Eisenbarth; J L Strominger; A S Fauci
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

6.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells.

Authors:  T Uchiyama; D L Nelson; T A Fleisher; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

Review 7.  Early events in cell-animal virus interactions.

Authors:  S Dales
Journal:  Bacteriol Rev       Date:  1973-06

8.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

9.  Tritium labeling of proteins to high specific radioactivity by reduction methylation.

Authors:  B F Tack; J Dean; D Eilat; P E Lorenz; A N Schechter
Journal:  J Biol Chem       Date:  1980-09-25       Impact factor: 5.157

10.  Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor.

Authors:  J E Gootenberg; F W Ruscetti; J W Mier; A Gazdar; R C Gallo
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307

View more
  17 in total

Review 1.  Covalent and noncovalent protein binding of drugs: implications for hepatic clearance, storage, and cell-specific drug delivery.

Authors:  D K Meijer; P van der Sluijs
Journal:  Pharm Res       Date:  1989-02       Impact factor: 4.200

Review 2.  Immunotherapy through the IL-2 receptor.

Authors:  H A Verheul; M Verveld; E S Bos
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

3.  Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy.

Authors:  R W Kozak; R W Atcher; O A Gansow; A M Friedman; J J Hines; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

4.  HTLV-I-associated diseases.

Authors:  P A Bunn
Journal:  West J Med       Date:  1989-05

Review 5.  Immunotoxins against solid tumors.

Authors:  R Pirker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

Review 6.  Immunoconjugates in the management of hairy cell leukemia.

Authors:  Robert J Kreitman; Ira Pastan
Journal:  Best Pract Res Clin Haematol       Date:  2015-10-09       Impact factor: 3.020

7.  Blockade of the interleukin-2 receptor by anti-Tac antibody inhibits the generation of antigen-nonspecific suppressor T cells in vitro.

Authors:  T Oh-Ishi; C K Goldman; J Misiti; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

Review 8.  Recent advances with Treg depleting fusion protein toxins for cancer immunotherapy.

Authors:  Pankaj Kumar; Amit Kumar; Sadiya Parveen; John R Murphy; William Bishai
Journal:  Immunotherapy       Date:  2019-07-30       Impact factor: 4.040

9.  Antitumor effects of an immunotoxin made with Pseudomonas exotoxin in a nude mouse model of human ovarian cancer.

Authors:  D J FitzGerald; M C Willingham; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 12.779

10.  A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells.

Authors:  D J FitzGerald; M C Willingham; C O Cardarelli; H Hamada; T Tsuruo; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 12.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.